Zeta Global Holdings Corp SEC Filings

Sight Sciences, Inc. (SGHT) filed a Form 144, providing notice of a proposed sale of restricted securities by an affiliate. The filing covers the planned disposition of 9,160 common shares, valued at approximately $38,235.67 based on prevailing market prices. The shares, which vested as restricted-stock compensation on 06/30/2025, are slated to be sold through Fidelity Brokerage Services on or about 07/03/2025 on NASDAQ.

With 51.7 million shares outstanding, the contemplated sale represents less than 0.02 % of total shares and therefore is unlikely to have a material impact on the float or trading dynamics. The filer reported no other insider sales in the past three months. While Form 144 sales signal insider liquidity activity, the modest size and compensation-related origin suggest routine portfolio management rather than a directional view on the company’s fundamentals.

Zeta Global Holdings Corp. (ZETA) | SEC Form 4 – 3 July 2025

Director Jeanine Silberblatt reported the grant of 9,907 Class A common shares on 1 July 2025. The award is structured as restricted stock that vests in four equal tranches: 1 July 2026, 1 Oct 2026, 1 Jan 2027 and 1 Apr 2027. No shares were sold and the transaction price is recorded at $0, indicating a compensation grant rather than an open-market purchase. Following the transaction, the director’s total beneficial ownership rises to 70,840 shares, all held directly. No derivative securities were reported.

The filing is routine board compensation, but it nonetheless increases insider equity alignment and signals continued board engagement through 2027.

Zeta Global Holdings Corp. (ZETA) – Form 4 insider transaction

On July 1, 2025, director William Landman reported two acquisitions of the company’s Class A common stock, both structured as equity compensation grants rather than open-market purchases.

• Restricted-stock award: 9,907 shares granted at a deemed price of $0.00. The award vests in four equal installments on 7/1/2026, 10/1/2026, 1/1/2027 and 4/1/2027.
• Quarterly director retainer: 1,614 restricted shares valued at $15.49 per share, issued under the 2021 Incentive Award Plan. Vesting: 25 % one year after grant; remaining 75 % in four equal quarterly installments beginning on the first anniversary.

Following these grants, direct beneficial ownership increases to 271,693 shares. In addition, Mr. Landman indirectly owns 607,165 shares through his spouse, bringing his total reported beneficial stake to roughly 878,858 shares.

The filing does not disclose any derivative security activity, sales, or open-market purchases. Given the modest size of the awards relative to ZETA’s ~207 million outstanding shares (per last 10-Q), dilution is immaterial. The grants mainly reflect routine director compensation and ongoing equity alignment rather than a signal of insider conviction.

Zeta Global Holdings Corp. (ZETA) filed a Form 4 indicating that director Imran Khan was granted 9,907 Class A common shares on 1 July 2025. The award was made at $0 cost as restricted stock and will vest in four equal tranches on 1 July 2026, 1 October 2026, 1 January 2027 and 1 April 2027. After the grant, Mr. Khan directly holds 31,148 shares and indirectly controls 55,000 additional shares through Proem Investments Master Fund LP. No derivative securities were reported. The filing represents routine director equity compensation rather than an open-market purchase and is unlikely to have a material impact on the company’s valuation or governance.

Citigroup Global Markets Holdings Inc., fully guaranteed by Citigroup Inc., is offering $3.72 million of Trigger Callable Yield Notes (CUSIP: 17332B777) linked to the least-performing of the EURO STOXX 50 (SX5E) and Nasdaq-100 (NDX) indices. The notes, priced at $10.00 each, settle on 8 July 2025, pay a fixed 8.15% p.a. coupon in monthly installments of $0.0679, and mature on 8 October 2026 unless called earlier.

Key structural terms

• Issuer call feature: From the third coupon date (8 Oct 2025) onward, the issuer may redeem the notes in whole at par plus the current coupon. The effective tenor could therefore be as short as three months.
• Downside threshold: 70% of the trade-date closing level for each index (SX5E 3,723.10; NDX 15,849.32). If, at final valuation (2 Oct 2026), the worst-performing index closes below its threshold and the notes were not called, principal is reduced 1-for-1 with the index loss, potentially to zero.
• No upside participation: Investor return is capped at the coupons; any index appreciation beyond threshold benefits only the issuer if the notes are not called.
• Credit & liquidity: The notes are unsecured, rank pari passu with Citigroup unsecured debt, are not FDIC-insured, and will not be listed on an exchange. Secondary liquidity depends solely on Citigroup Global Markets Inc. (CGMI) and may be limited.
• Pricing economics: Estimated value on the trade date is $9.868, implying a 1.32% issue-premium that reflects the 1.0% underwriting fee and internal funding spread. CGMI expects a four-month post-issuance adjustment period during which quoted bid values include a temporary hedging mark-up.

Risk highlights

• Investors face full downside exposure to the worst index if not called, with no benefit from the better-performing index.
• Higher coupon compensates for elevated volatility and low correlation between SX5E and NDX; historical correlation is modest, increasing the chance that at least one index breaches its threshold.
• Early redemption risk: Should market rates fall or index performance be favorable to the issuer, the notes are likely to be called, truncating income potential and forcing reinvestment at lower prevailing yields.
• Tax treatment is uncertain; Citigroup intends to treat each note as a deposit plus written put. Non-U.S. holders could face 30% withholding if alternative IRS views prevail.

Overall, the notes suit investors seeking enhanced coupon income and willing to accept issuer credit risk, early-call reinvestment risk, and potentially substantial principal loss tied solely to the weaker of two major equity benchmarks.

Epsilon Energy Ltd. (EPSN) – Form 4 insider filing

Chief Executive Officer and Director Jason Stabell reported the automatic issuance of restricted stock that vested on 1 July 2025. Two separate grants became unrestricted:

• 6,098 common shares from a 1 July 2022 award (footnote 1)
• 18,727 common shares from a 1 July 2023 award (footnote 2)

The transactions are coded “A” (acquisition) and were executed at $0, reflecting share issuance rather than market purchases.

Following these events, Stabell’s direct holdings increased to 271,671 common shares. He also reports 470,339 shares held indirectly through an LLC, bringing his total disclosed beneficial ownership to roughly 742,010 shares.

No derivative securities were involved, and there were no dispositions. Because the shares stem from previously approved compensation plans, the filing signals continued equity alignment but does not reflect an incremental cash investment by the insider.

UBS AG is offering $200,000 of Trigger Autocallable Contingent Yield Notes linked to the common stock of Delta Air Lines, Inc. (DAL), maturing 8 July 2026. The Notes are senior unsecured obligations of UBS AG’s London branch and are not FDIC-insured. Investors receive a fixed contingent coupon of 16.49% p.a. (≈ 4.123% quarterly, or $0.4123 per $10 note) only when DAL’s closing price on a quarterly observation date is at least the coupon barrier of $35.60 (70 % of the initial level). If the DAL share price on any observation date before final maturity equals or exceeds the initial level of $50.86, UBS automatically calls the Notes and repays principal plus the applicable coupon; no further payments are made thereafter.

Principal at risk: Should the Notes remain outstanding until maturity and DAL close below the 70 % downside threshold ($35.60) on the final valuation date, investors are exposed to the full percentage decline of DAL, down to a total loss of principal. Principal is protected only if DAL closes at or above the threshold on the final valuation date.

Key economics: • Issue price: $10.00; estimated initial value: $9.79 (reflects underwriting discount of $0.15 and internal funding spread). • Minimum investment: 100 Notes ($1,000). • Quarterly observation dates: 6 Oct 2025, 6 Jan 2026, 6 Apr 2026, 6 Jul 2026. • Settlement 8 Jul 2025 (T+2). • CUSIP: 90309M522, ISIN: US90309M5224.

Risk highlights: Investors face (1) significant market risk equal to direct equity exposure to DAL shares, (2) credit risk to UBS AG, (3) liquidity risk because the Notes are not exchange-listed and secondary market making is discretionary, (4) valuation risk—the issue price exceeds the model value, and (5) potential adverse tax treatment; coupons are expected to be taxed as ordinary income, and overall treatment is uncertain.

Suitability: The Notes may appeal to investors who:

• seek enhanced conditional income over ~1 year;
• are moderately bullish or neutral on DAL, expecting the share to remain above $35.60;
• can tolerate equity-like downside, limited upside (no participation above coupons) and UBS credit risk;
• understand that coupons may be skipped and principal can be lost.

Illustrative performance: • If DAL ≥ $50.86 on the first observation date, investors receive $10.4123 (4.123 % return) and the Notes are called after ~3 months. • If never called and DAL ≥ $35.60 at maturity, total return equals aggregate coupons (max 8.246 %). • If DAL ends at $33.82 (–33.5 %), principal repayment falls to $6.65 plus one earlier coupon, implying a –29.38 % total loss.

Regulatory & distribution: FINRA Rule 5121 conflict of interest disclosure applies; sales to EEA/UK retail investors are prohibited. UBS Securities LLC and UBS Financial Services Inc. will market make on a best-efforts basis; bid–ask spreads and internal funding rates may depress any resale price.

Zeta Global Holdings has reported a Form 144 notice for a proposed sale of securities. A trust is planning to sell 532,525 shares of Class A Common Stock with an aggregate market value of $7,551,204.50 through Merrill Lynch on the NYSE. The approximate date of sale is set for June 20, 2025.

The securities were originally acquired on April 3, 2024, through estate planning transfers. The filing also discloses that the same trust (Family Trust III) has already sold 127,000 shares for gross proceeds of $1,807,325.19 during the past three months.

Key details:

• Total outstanding shares: 235,544,133
• Trading venue: NYSE
• Broker: Merrill Lynch, New York
• Securities originally acquired from trust settlor who obtained them in January 2015